Previous close | 201.99 |
Open | 201.21 |
Bid | 202.43 x 300 |
Ask | 202.54 x 100 |
Day's range | 198.11 - 205.36 |
52-week range | 189.44 - 319.76 |
Volume | |
Avg. volume | 1,260,329 |
Market cap | 29.478B |
Beta (5Y monthly) | -0.01 |
PE ratio (TTM) | 25.31 |
EPS (TTM) | 8.00 |
Earnings date | 23 Jul 2024 - 29 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 287.48 |
Insightful Analysis of Biogen Inc's Financials and Strategic Positioning
CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for TOFIDENCE™ (tocilizumab), a biosimilar monoclonal antibody referencing ROACTEMRA®1. The intravenous formulation of TOFID
Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.